METHODS AND COMPOSITIONS COMPRISING A KRASG12C INHIBITOR AND A PD-L1 BINDING ANTAGONIST FOR TREATING LUNG CANCER
Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab).
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | English |
Published |
19.05.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab). |
---|---|
Bibliography: | Application Number: US202117524049 |